EMEA-002163-PIP01-17
Key facts
| Active substance |
Human normal immunoglobulin
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0246/2017
|
| PIP number |
EMEA-002163-PIP01-17
|
| Pharmaceutical form(s) |
Solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Primary Immunodeficiency (PID)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Kedrion S.p.A.
Tel. +39 0583 1969697
E-mail: info@kedrion.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|